Streetbeat News

Analyst Ratings

BCAB

HC Wainwright & Co. analyst Arthur He has reiterated a 'Buy' rating on BioAtla (NASDAQ:BCAB) and maintained a price target of $17.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:48 am

LSEA

Barclays analyst Matthew Bouley maintains an Equal-Weight rating on Landsea Homes (NASDAQ:LSEA) and raises the price target from $9 to $12.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:48 am

TRDA

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a 'Buy' rating on Entrada Therapeutics (NASDAQ:TRDA) and maintained a $25 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:48 am

IMXI

IntL Money Express (NASDAQ:IMXI) reported Q2 adjusted earnings of $0.50 per share, missing the analyst consensus estimate of $0.51 by 1.96%. The company also reported quarterly sales of $169.15 million, missing the analyst consensus estimate of $171.35 million by 1.28%. However, both earnings and sales showed an increase compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:48 am

HRMY

Needham analyst Ami Fadia has reiterated a 'Buy' rating on Harmony Biosciences (NASDAQ:HRMY) and maintained a price target of $66.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:48 am

RVMD

Needham analyst Ami Fadia maintains a Buy rating on Revolution Medicines (NASDAQ:RVMD) and raises the price target from $31 to $35.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:48 am

FWRG

Barclays analyst Jeffrey Bernstein maintains an Overweight rating on First Watch Restaurant Gr (NASDAQ:FWRG) and raises the price target from $21 to $23.

Portfolio Pulse from Benzinga Newsdesk

August 04, 2023 | 10:48 am

SYY

Stephens & Co. analyst Joshua Long has reiterated an Overweight rating on Sysco (NYSE:SYY) and maintained a $90 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:47 am

AQB

HC Wainwright & Co. analyst Kevin Dede has reiterated a 'Buy' rating on AquaBounty Techs (NASDAQ:AQB) and maintained a $1 price target.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:47 am

NERV

HC Wainwright & Co. analyst Douglas Tsao maintains a Neutral rating on Minerva Neurosciences (NASDAQ:NERV) and raises the price target from $8 to $11.

Portfolio Pulse from richadhand@benzinga.com

August 04, 2023 | 10:47 am